Ozempic and its cousins have already upended the food industry. Now they’re coming for your closet. Bernstein analysts dropped a research note on Friday estimating that GLP-1 weight-loss drugs could boost annual U.S. clothing spending by up to $13 billion — and the ripple effects across retail could be massive.
The logic is straightforward but the scale is staggering. Tens of millions of Americans are now on drugs like Wegovy and Zepbound, and they’re losing serious weight. When you drop two or three clothing sizes, your entire wardrobe becomes obsolete overnight. You’re not just buying a new pair of jeans — you’re replacing everything from workout gear to business casual to winter coats. Multiply that across the roughly 9 million Americans currently on GLP-1 medications, with that number projected to grow significantly, and you get a spending wave that retailers are just beginning to price in.
Bernstein flagged several names positioned to benefit. Nike and Lululemon are obvious plays — people who lose weight tend to become more active, and activewear is typically the first wardrobe category they refresh. But the more interesting call is on discounters like Burlington Stores. A lot of GLP-1 users aren’t wealthy — insurance coverage is spotty and the drugs themselves can cost $1,000+ per month out of pocket. These consumers will need to rebuild wardrobes on a budget, which plays directly into the off-price model.
There’s a second-order effect worth watching too. The apparel industry has spent years dealing with stagnant growth in the U.S. market, where most consumers already own more clothes than they need. GLP-1 drugs essentially create a forced replacement cycle — a rare catalyst in an industry that’s been struggling to generate organic demand. It’s not unlike what happens after a natural disaster drives replacement spending on homes and cars, except this time the “disaster” is millions of people getting healthier.
Not everyone wins equally. Plus-size retailers and brands heavily indexed to larger sizing could face headwinds as their core demographic literally shrinks. And the spending bump may prove lumpy rather than steady — once someone rebuilds their wardrobe, the incremental spending fades until the next size change.
Still, $13 billion in incremental demand is nothing to sneeze at in an industry where single-digit growth is considered a win. For investors watching the GLP-1 revolution, the playbook keeps expanding beyond pharma stocks. First it was food companies adjusting to smaller portion sizes. Now it’s retailers preparing for a generation of consumers who need new clothes. The Ozempic economy is real — and it’s just getting started.
